Arcutis Biotherapeutics (ARQT) Total Non-Current Liabilities (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Total Non-Current Liabilities of $269.9 million for Q1 2026, up 34.23% year-over-year from $201.1 million in Q1 2025, and up 11.05% quarter-over-quarter from $243.1 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $269.9 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 34.23% year-over-year to $269.9 million; the TTM figure through Mar 2026 stood at $269.9 million (up 34.23% YoY), while the FY2025 annual figure was $243.1 million, up 27.41% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $269.9 million, up from $243.1 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $280.3 million in Q3 2024, with the low at $105.1 million in Q2 2022.
- The 5-year median for Total Non-Current Liabilities is $238.9 million (2022), against an average of $219.1 million.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities soared 892.99% in 2022, then dropped 24.25% in 2024.
- Arcutis Biotherapeutics' Total Non-Current Liabilities stood at $239.7 million in 2022, then advanced by 5.07% to $251.8 million in 2023, then slipped by 24.25% to $190.8 million in 2024, then gained by 27.41% to $243.1 million in 2025, then climbed by 11.05% to $269.9 million in 2026.
- Business Quant data shows ARQT's Total Non-Current Liabilities at $269.9 million in Q1 2026, $243.1 million in Q4 2025, and $212.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 267.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 267.53 Mn |
| Mar 31, 2026 | 269.92 Mn |
| Dec 31, 2025 | 243.06 Mn |
| Sep 30, 2025 | 212.54 Mn |
| Jun 30, 2025 | 213.10 Mn |
| Mar 31, 2025 | 201.09 Mn |
| Dec 31, 2024 | 190.78 Mn |
| Sep 30, 2024 | 280.29 Mn |
| Jun 30, 2024 | 258.14 Mn |
| Mar 31, 2024 | 253.29 Mn |
| Dec 31, 2023 | 251.85 Mn |
| Dec 31, 2022 | 239.69 Mn |
| Sep 30, 2022 | 238.14 Mn |
| Jun 30, 2022 | 105.07 Mn |
| Mar 31, 2022 | 110.32 Mn |
| Dec 31, 2021 | 110.45 Mn |
| Sep 30, 2021 | 23.98 Mn |
| Jun 30, 2021 | 18.38 Mn |
| Mar 31, 2021 | 20.36 Mn |
| Dec 31, 2020 | 27.57 Mn |